Studies have shown that active fund managers routinely underperform the S&P500 index*​

Autolus Therapeutics plc (NASDAQ: AUTL)

AUTL Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
56.70%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%

AUTL Stock Analysis

AUTL PE Ratio:

AUTL PEG Ratio: Not Available

AUTL Forward EPS Growth (12 month): 0.00%

AUTL PS Ratio: 4.7

AUTL PSG Ratio: 0.1

AUTL Forward Revenue Growth (12 month): 62.50%

AUTL Articles

No data was found